In addition to these studies, emerging evidence has demonstrated that amlexanox, a small molecule regulator used to treat ulcers and asthma, can selectively inhibit IKBKE kinase activation through competing with IKBKE on the ATP‐binding site.91 Furthermore, Challa et al56 confirmed that combining amlexanox with the MEK inhibitor AZD6244 inhibits the in vivo growth of xenografted NSCLC cells targeting activating EGFR mutations, including EGFRT790M. Here, EGFR is linked to non-small cell lung carcinoma.